<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://m2.mtmt.hu/xsl/gui3.xsl" ?>
<myciteResult>
  <serverUrl>https://m2.mtmt.hu/</serverUrl>
  <labelLang>eng</labelLang>
  <responseDate>2026-06-13 04:56</responseDate>
  <content>
    <publication>
      <otype>JournalArticle</otype>
      <mtid>33754849</mtid>
      <status>APPROVED</status>
      <published>true</published>
      <comment>Department of Bioinformatics, Semmelweis University, Tűzoltó utca 7-9, Budapest, 1094, Hungary            
            Doctoral School of Pathological Sciences, Semmelweis University, Üllői út 26, Budapest, 1085, Hungary            
            National Laboratory for Drug Research and Development, Magyar tudósok körútja 2 1117, Budapest, Hungary            
            Research Centre for Natural Sciences, Oncology Biomarker Research Group, Institute of Enzymology, Eötvös Loránd Research Network, Magyar Tudósok körútja 2, Budapest, 1117, Hungary            
            Department of Pediatrics, Semmelweis University, Tűzoltó utca 7-9, Budapest, 1094, Hungary            
            Cited By :7            
            Export Date: 7 February 2024            
            CODEN: APSCG            
            Correspondence Address: Győrffy, B.; Department of Bioinformatics, Tűzoltó utca 7-9, Hungary; email: gyorffy.balazs@med.semmelweis-univ.hu            
            Chemicals/CAS: atezolizumab, 1380723-44-3; durvalumab, 1428935-60-7; fibroblast growth factor receptor 3, 306781-00-0; ipilimumab, 477202-00-9; MutL protein homolog 1, 155577-96-1; nivolumab, 946414-94-4; pembrolizumab, 1374853-91-4; protein bcl 2, 219306-68-0; histone lysine methyltransferase, 9076-80-6; Biomarkers, Tumor; Histone-Lysine N-Methyltransferase; Ipilimumab; SETD7 protein, human            
            Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA            
            Funding details: National Research, Development and Innovation Office, 2020-1.1.6-JÖVŐ-2021-00013, KDP-14-3/PALY-2021, RRF-2.3.1-21-2022-00015, TKP-2021-NVA-15            
            Funding text 1: This project was supported by the Hungary National Research, Development and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015, TKP-2021-NVA-15, and 2020-1.1.6-JÖVŐ-2021-00013). Project no. KDP-14-3/PALY-2021 has been implemented with the support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, financed under the KDP-2020 funding scheme. The authors acknowledge the support of ELIXIR-Hungary ( https://www.bioinformatics.hu/ ) and thank Viktoria Lakatos for the careful English editing of the manuscript.            
            Funding text 2: This project was supported by the Hungary National Research, Development and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015, TKP-2021-NVA-15, and 2020-1.1.6-JÖVŐ-2021-00013). Project no. KDP-14-3/PALY-2021 has been implemented with the support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, financed under the KDP-2020 funding scheme. The authors acknowledge the support of ELIXIR-Hungary (https://www.bioinformatics.hu/ ) and thank Viktoria Lakatos for the careful English editing of the manuscript.</comment>
      <unhandledTickets>0</unhandledTickets>
      <deleted>false</deleted>
      <lastRefresh>2026-06-09T09:39:23.118+0000</lastRefresh>
      <lastModified>2024-02-06T12:54:16.564+0000</lastModified>
      <created>2023-04-17T12:48:46.953+0000</created>
      <creator>
        <snippet>true</snippet>
        <mtid>10019974</mtid>
        <familyName>xSzűts</familyName>
        <givenName>xFerencné</givenName>
        <link>/api/admin/10019974</link>
        <otype>Admin</otype>
        <label>xFerencné xSzűts (xSE_AOK_2Gyerek_Admin5_SzFné, admin)</label>
        <published>true</published>
        <oldId>10019974</oldId>
      </creator>
      <lastDuplumSearch>2026-02-09T20:32:11.894+0000</lastDuplumSearch>
      <tempLockers>
        <otype>Admin</otype>
        <mtid>10014568</mtid>
        <link>/api/admin/10014568</link>
        <label>Andrea Vándor (VA, admin)</label>
        <familyName>Vándor</familyName>
        <givenName>Andrea</givenName>
        <published>true</published>
        <oldId>10014568</oldId>
        <snippet>true</snippet>
      </tempLockers>
      <tempLocked>2024-04-04T10:41:14.495+0000</tempLocked>
      <core>true</core>
      <publicationPending>false</publicationPending>
      <type>
        <snippet>true</snippet>
        <mtid>24</mtid>
        <code>24</code>
        <link>/api/publicationtype/24</link>
        <otype>PublicationType</otype>
        <label>Journal Article</label>
        <listPosition>1</listPosition>
        <published>true</published>
        <oldId>24</oldId>
        <otypeName>JournalArticle</otypeName>
      </type>
      <subType>
        <snippet>true</snippet>
        <mtid>10000059</mtid>
        <nameEng>Article</nameEng>
        <docType>
          <snippet>true</snippet>
          <mtid>24</mtid>
          <code>24</code>
          <link>/api/publicationtype/24</link>
          <otype>PublicationType</otype>
          <label>Journal Article</label>
          <listPosition>1</listPosition>
          <published>true</published>
          <oldId>24</oldId>
          <otypeName>JournalArticle</otypeName>
        </docType>
        <link>/api/subtype/10000059</link>
        <name>Szakcikk</name>
        <otype>SubType</otype>
        <label>Article (Journal Article)</label>
        <listPosition>101</listPosition>
        <published>true</published>
        <oldId>10000059</oldId>
      </subType>
      <category>
        <snippet>true</snippet>
        <mtid>1</mtid>
        <link>/api/category/1</link>
        <otype>Category</otype>
        <label>Scientific</label>
        <published>true</published>
        <oldId>1</oldId>
      </category>
      <firstAuthor>Kovács, Szonja Anna</firstAuthor>
      <title>Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors</title>
      <journal>
        <snippet>true</snippet>
        <sciIndexed>true</sciIndexed>
        <link>/api/journal/10551</link>
        <reviewType>REVIEWED</reviewType>
        <label>ACTA PHARMACOLOGICA SINICA 1671-4083 1745-7254</label>
        <published>true</published>
        <hungarian>false</hungarian>
        <oldId>10551</oldId>
        <noIF>false</noIF>
        <mtid>10551</mtid>
        <scopusIndexed>true</scopusIndexed>
        <pIssn>1671-4083</pIssn>
        <eIssn>1745-7254</eIssn>
        <otype>Journal</otype>
        <lang>FOREIGN</lang>
      </journal>
      <volume>44</volume>
      <issue>9</issue>
      <firstPage>1879</firstPage>
      <lastPage>1889</lastPage>
      <firstPageOrInternalIdForSort>1879</firstPageOrInternalIdForSort>
      <pageLength>11</pageLength>
      <publishedYear>2023</publishedYear>
      <abstractText>Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor types. Biomarkers are biological indicators used to select patients for a systemic anticancer treatment, but there are only a few clinically useful biomarkers such as PD-L1 expression and tumor mutational burden, which can be used to predict immunotherapy response. In this study, we established a database consisting of both gene expression and clinical data to identify biomarkers of response to anti-PD-1, anti-PD-L1, and anti-CTLA-4 immunotherapies. A GEO screening was executed to identify datasets with simultaneously available clinical response and transcriptomic data regardless of cancer type. The screening was restricted to the studies involving administration of anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab) or anti-CTLA-4 (ipilimumab) agents. Receiver operating characteristic (ROC) analysis and Mann-Whitney test were executed across all genes to identify features related to therapy response. The database consisted of 1434 tumor tissue samples from 19 datasets with esophageal, gastric, head and neck, lung, and urothelial cancers, plus melanoma. The strongest druggable gene candidates linked to anti-PD-1 resistance were SPIN1 (AUC = 0.682, P  = 9.1E-12), SRC (AUC = 0.667, P  = 5.9E-10), SETD7 (AUC = 0.663, P  = 1.0E-09), FGFR3 (AUC = 0.657, P  = 3.7E-09), YAP1 (AUC = 0.655, P  = 6.0E-09), TEAD3 (AUC = 0.649, P  = 4.1E-08) and BCL2 (AUC = 0.634, P  = 9.7E-08). In the anti-CTLA-4 treatment cohort, BLCAP (AUC = 0.735, P  = 2.1E-06) was the most promising gene candidate. No therapeutically relevant target was found to be predictive in the anti-PD-L1 cohort. In the anti-PD-1 group, we were able to confirm the significant correlation with survival for the mismatch-repair genes MLH1 and MSH6 . A web platform for further analysis and validation of new biomarker candidates was set up and available at https://www.rocplot.com/immune . In summary, a database and a web platform were established to investigate biomarkers of immunotherapy response in a large cohort of solid tumor samples. Our results could help to identify new patient cohorts eligible for immunotherapy.</abstractText>
      <fundings>
        <funding>
          <otype>Funding</otype>
          <mtid>2026038</mtid>
          <link>/api/funding/2026038</link>
          <label>(Open access funding provided by Semmelweis University)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2028838</mtid>
          <link>/api/funding/2028838</link>
          <label>Nemzeti Gyógyszerkutatási és Fejlesztési Laboratórium(PharmaLab) Funder: NRDIO</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2035554</mtid>
          <link>/api/funding/2035554</link>
          <label>National Laboratory of Translational Neuroscience(RRF-2.3.1-21-2022-00015)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2035555</mtid>
          <link>/api/funding/2035555</link>
          <label>(TKP-2021-NVA-15) Funder: NRDIO</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2035556</mtid>
          <link>/api/funding/2035556</link>
          <label>(2020-1.1.6-JOVO-2021-00013)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2035557</mtid>
          <link>/api/funding/2035557</link>
          <label>(KDP-14-3/PALY-2021)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2035558</mtid>
          <link>/api/funding/2035558</link>
          <label>(ELIXIR Hungary)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
      </fundings>
      <digital>true</digital>
      <printed>true</printed>
      <collaboration>NATIONAL</collaboration>
      <sourceYear>2023</sourceYear>
      <foreignEdition>true</foreignEdition>
      <foreignLanguage>true</foreignLanguage>
      <fullPublication>true</fullPublication>
      <conferencePublication>false</conferencePublication>
      <nationalOrigin>true</nationalOrigin>
      <missingAuthor>false</missingAuthor>
      <oaType>GOLD</oaType>
      <oaCheckDate>2026-06-09</oaCheckDate>
      <oaFree>true</oaFree>
      <oaLink>https://doi.org/10.1038/s41401-023-01079-6</oaLink>
      <citationCount>156</citationCount>
      <citationCountUnpublished>0</citationCountUnpublished>
      <citationCountWoOther>156</citationCountWoOther>
      <independentCitCountWoOther>150</independentCitCountWoOther>
      <nationalOriginCitationCount>6</nationalOriginCitationCount>
      <foreignEditionCitationCount>155</foreignEditionCitationCount>
      <doiCitationCount>156</doiCitationCount>
      <wosCitationCount>150</wosCitationCount>
      <scopusCitationCount>101</scopusCitationCount>
      <wosScopusCitationCount>156</wosScopusCitationCount>
      <wosScopusCitationCountWoOther>156</wosScopusCitationCountWoOther>
      <wosScopusIndependentCitationCount>150</wosScopusIndependentCitationCount>
      <wosScopusIndependentCitationCountWoOther>150</wosScopusIndependentCitationCountWoOther>
      <independentCitationCount>150</independentCitationCount>
      <selfCitationCount>6</selfCitationCount>
      <unhandledCitationCount>0</unhandledCitationCount>
      <citingPubCount>156</citingPubCount>
      <independentCitingPubCount>150</independentCitingPubCount>
      <citingPubCountWoOther>156</citingPubCountWoOther>
      <independentCitingPubCountWoOther>150</independentCitingPubCountWoOther>
      <unhandledCitingPubCount>0</unhandledCitingPubCount>
      <citedPubCount>4</citedPubCount>
      <citedCount>4</citedCount>
      <pubStats>
        <types>
          <type>Folyóiratcikk</type>
          <typeEng>Journal Article</typeEng>
          <code>24</code>
          <count>155</count>
        </types>
        <types>
          <type>Könyvrészlet</type>
          <typeEng>Chapter in Book</typeEng>
          <code>25</code>
          <count>1</count>
        </types>
        <types>
          <type>Könyv</type>
          <typeEng>Book</typeEng>
          <code>23</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb konferenciaközlemény</type>
          <typeEng>Conference paper</typeEng>
          <code>31</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb konferenciakötet</type>
          <typeEng>Conference proceedings</typeEng>
          <code>32</code>
          <count>0</count>
        </types>
        <types>
          <type>Oltalmi formák</type>
          <typeEng>Protection forms</typeEng>
          <code>26</code>
          <count>0</count>
        </types>
        <types>
          <type>Disszertáció</type>
          <typeEng>Thesis</typeEng>
          <code>28</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb</type>
          <typeEng>Miscellaneous</typeEng>
          <code>29</code>
          <count>0</count>
        </types>
        <types>
          <type>Alkotás</type>
          <typeEng>Achievement</typeEng>
          <code>22</code>
          <count>0</count>
        </types>
        <types>
          <type>Kutatási adat</type>
          <typeEng>Research data</typeEng>
          <code>33</code>
          <count>0</count>
        </types>
        <citationTypes>
          <type>Folyóiratcikk</type>
          <typeEng>Journal Article</typeEng>
          <code>24</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Könyvrészlet</type>
          <typeEng>Chapter in Book</typeEng>
          <code>25</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Könyv</type>
          <typeEng>Book</typeEng>
          <code>23</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb konferenciaközlemény</type>
          <typeEng>Conference paper</typeEng>
          <code>31</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb konferenciakötet</type>
          <typeEng>Conference proceedings</typeEng>
          <code>32</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Oltalmi formák</type>
          <typeEng>Protection forms</typeEng>
          <code>26</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Disszertáció</type>
          <typeEng>Thesis</typeEng>
          <code>28</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb</type>
          <typeEng>Miscellaneous</typeEng>
          <code>29</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Alkotás</type>
          <typeEng>Achievement</typeEng>
          <code>22</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Kutatási adat</type>
          <typeEng>Research data</typeEng>
          <code>33</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <years>
          <year>2023</year>
          <publicationCount>0</publicationCount>
          <citationCount>6</citationCount>
          <independentCitationCount>6</independentCitationCount>
          <citingPubCount>6</citingPubCount>
          <independentCitingPubCount>6</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2024</year>
          <publicationCount>0</publicationCount>
          <citationCount>46</citationCount>
          <independentCitationCount>44</independentCitationCount>
          <citingPubCount>46</citingPubCount>
          <independentCitingPubCount>44</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2025</year>
          <publicationCount>0</publicationCount>
          <citationCount>65</citationCount>
          <independentCitationCount>61</independentCitationCount>
          <citingPubCount>65</citingPubCount>
          <independentCitingPubCount>61</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2026</year>
          <publicationCount>0</publicationCount>
          <citationCount>39</citationCount>
          <independentCitationCount>39</independentCitationCount>
          <citingPubCount>39</citingPubCount>
          <independentCitingPubCount>39</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
      </pubStats>
      <ratingsForSort>D1</ratingsForSort>
      <hasCitationDuplums>false</hasCitationDuplums>
      <inSelectedPubs>10000109,10063867</inSelectedPubs>
      <importDuplum>false</importDuplum>
      <importOverwritten>false</importOverwritten>
      <importSkipped>false</importSkipped>
      <userChangeableUntil>2023-07-09T08:04:07.595+0000</userChangeableUntil>
      <directInstitutesForSort>Bioinformatika Tanszék (SE / AOK / I); Doktori Iskola (SE); Gyermekgyógyászati Klinika (SE / AOK / K); Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI)</directInstitutesForSort>
      <ownerAuthorCount>3</ownerAuthorCount>
      <ownerInstituteCount>26</ownerInstituteCount>
      <directInstituteCount>4</directInstituteCount>
      <authorCount>3</authorCount>
      <contributorCount>0</contributorCount>
      <hasQualityFactor>true</hasQualityFactor>
      <tempLockerIds>10014568</tempLockerIds>
      <languages>
        <language>
          <otype>Language</otype>
          <mtid>10002</mtid>
          <link>/api/language/10002</link>
          <label>English</label>
          <name>Angol</name>
          <nameEng>English</nameEng>
          <published>true</published>
          <oldId>2</oldId>
          <snippet>true</snippet>
        </language>
      </languages>
      <authorships>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>107359545</mtid>
          <link>/api/authorship/107359545</link>
          <label>Kovács, Szonja Anna [Kovács, Szonja Anna (Molekuláris biológia), author] Enzim_417 (IMLS); Bioinformatika Tanszék (SU / FM / I); School of PhD Studies (SU)</label>
          <listPosition>1</listPosition>
          <share>0.333</share>
          <first>true</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10081093</mtid>
            <link>/api/author/10081093</link>
            <label>Szonja Anna Kovács (Molekuláris biológia)</label>
            <familyName>Kovács</familyName>
            <givenName>Szonja Anna</givenName>
            <published>true</published>
            <snippet>true</snippet>
          </author>
          <familyName>Kovács</familyName>
          <givenName>Szonja Anna</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>107359546</mtid>
          <link>/api/authorship/107359546</link>
          <label>Fekete, János Tibor [Fekete, János Tibor (Prediktív biomark...), author] Enzim_417 (IMLS)</label>
          <listPosition>2</listPosition>
          <share>0.333</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10063867</mtid>
            <link>/api/author/10063867</link>
            <label>János Tibor Fekete (Prediktív biomarkerek)</label>
            <familyName>Fekete</familyName>
            <givenName>János Tibor</givenName>
            <published>true</published>
            <oldId>10063867</oldId>
            <snippet>true</snippet>
          </author>
          <familyName>Fekete</familyName>
          <givenName>János Tibor</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>107359547</mtid>
          <link>/api/authorship/107359547</link>
          <label>Győrffy, Balázs ✉ [Győrffy, Balázs (Onkológia), author] Enzim_417 (IMLS); Bioinformatika Tanszék (SU / FM / I); Department of Pediatrics (SU / FM / C)</label>
          <listPosition>3</listPosition>
          <share>0.333</share>
          <first>false</first>
          <last>true</last>
          <corresponding>true</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10000109</mtid>
            <link>/api/author/10000109</link>
            <label>Balázs Győrffy (Onkológia)</label>
            <familyName>Győrffy</familyName>
            <givenName>Balázs</givenName>
            <published>true</published>
            <oldId>10000109</oldId>
            <snippet>true</snippet>
          </author>
          <familyName>Győrffy</familyName>
          <givenName>Balázs</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
      </authorships>
      <identifiers>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23383329</mtid>
          <link>/api/publicationidentifier/23383329</link>
          <label>DOI: 10.1038/s41401-023-01079-6</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>6</mtid>
            <link>/api/publicationsource/6</link>
            <label>DOI</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10001</mtid>
              <link>/api/publicationsourcetype/10001</link>
              <label>DOI</label>
              <mayHaveOa>true</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>DOI</name>
            <nameEng>DOI</nameEng>
            <linkPattern>https://doi.org/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>6</oldId>
            <snippet>true</snippet>
          </source>
          <oaType>GOLD</oaType>
          <oaFree>true</oaFree>
          <validState>IDENTICAL</validState>
          <idValue>10.1038/s41401-023-01079-6</idValue>
          <realUrl>https://doi.org/10.1038/s41401-023-01079-6</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23588395</mtid>
          <link>/api/publicationidentifier/23588395</link>
          <label>WoS: 000970965200001</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>1</mtid>
            <link>/api/publicationsource/1</link>
            <label>WoS</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>WoS</name>
            <nameEng>WoS</nameEng>
            <linkPattern>https://www.webofscience.com/wos/woscc/full-record/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>1</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>000970965200001</idValue>
          <realUrl>https://www.webofscience.com/wos/woscc/full-record/000970965200001</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23422106</mtid>
          <link>/api/publicationidentifier/23422106</link>
          <label>Scopus: 85152646595</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>3</mtid>
            <link>/api/publicationsource/3</link>
            <label>Scopus</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>Scopus</name>
            <nameEng>Scopus</nameEng>
            <linkPattern>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>3</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>85152646595</idValue>
          <realUrl>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85152646595</realUrl>
          <published>true</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23422107</mtid>
          <link>/api/publicationidentifier/23422107</link>
          <label>PubMed: 37055532</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>17</mtid>
            <link>/api/publicationsource/17</link>
            <label>PubMed</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>PubMed</name>
            <nameEng>PubMed</nameEng>
            <linkPattern>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=@@@&amp;dopt=Abstract</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>17</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>37055532</idValue>
          <realUrl>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=37055532&amp;dopt=Abstract</realUrl>
          <published>true</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>31391742</mtid>
          <link>/api/publicationidentifier/31391742</link>
          <label>Other URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152646595&amp;doi=10.1038%2Fs41401-023-01079-6&amp;partnerID=40&amp;md5=976dbeadcfdb60024eec42b09b6cb2c2</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>40</mtid>
            <link>/api/publicationsource/40</link>
            <label>Other URL</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10006</mtid>
              <link>/api/publicationsourcetype/10006</link>
              <label>Link</label>
              <mayHaveOa>true</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>Egyéb URL</name>
            <nameEng>Other URL</nameEng>
            <linkPattern>@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>40</oldId>
            <snippet>true</snippet>
          </source>
          <oaType>NONE</oaType>
          <validState>IDENTICAL</validState>
          <idValue>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152646595&amp;doi=10.1038%2Fs41401-023-01079-6&amp;partnerID=40&amp;md5=976dbeadcfdb60024eec42b09b6cb2c2</idValue>
          <realUrl>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152646595&amp;doi=10.1038%2Fs41401-023-01079-6&amp;partnerID=40&amp;md5=976dbeadcfdb60024eec42b09b6cb2c2</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
      </identifiers>
      <ratings>
        <rating>
          <otype>SjrRating</otype>
          <mtid>11397015</mtid>
          <link>/api/sjrrating/11397015</link>
          <label>sjr:D1 (2023) Scopus - Medicine (miscellaneous) ACTA PHARMACOLOGICA SINICA 1671-4083 1745-7254</label>
          <listPos>155</listPos>
          <rankValue>0.1</rankValue>
          <type>journal</type>
          <ratingType>
            <otype>RatingType</otype>
            <mtid>10002</mtid>
            <link>/api/ratingtype/10002</link>
            <label>sjr</label>
            <code>sjr</code>
            <published>true</published>
            <snippet>true</snippet>
          </ratingType>
          <subject>
            <otype>ClassificationExternal</otype>
            <mtid>2701</mtid>
            <link>/api/classificationexternal/2701</link>
            <label>Scopus - Medicine (miscellaneous)</label>
            <published>true</published>
            <oldId>2701</oldId>
            <snippet>true</snippet>
          </subject>
          <ranking>D1</ranking>
          <calculation>DIRECT</calculation>
          <published>true</published>
          <snippet>true</snippet>
        </rating>
      </ratings>
      <references>
        <reference>
          <otype>Reference</otype>
          <mtid>40220395</mtid>
          <link>/api/reference/40220395</link>
          <label>1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801., DOI: 10.1038/s41467-020-17670-y</label>
          <listPosition>1</listPosition>
          <doi>10.1038/s41467-020-17670-y</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220396</mtid>
          <link>/api/reference/40220396</link>
          <label>2. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6., DOI: 10.1126/science.271.5256.1734</label>
          <listPosition>2</listPosition>
          <doi>10.1126/science.271.5256.1734</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220397</mtid>
          <link>/api/reference/40220397</link>
          <label>3. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T-cell activation. Immunity. 1994;1:405–13., DOI: 10.1016/1074-7613(94)90071-X</label>
          <listPosition>3</listPosition>
          <doi>10.1016/1074-7613(94)90071-X</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220398</mtid>
          <link>/api/reference/40220398</link>
          <label>4. Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23:39., DOI: 10.1208/s12248-021-00574-0</label>
          <listPosition>4</listPosition>
          <doi>10.1208/s12248-021-00574-0</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220399</mtid>
          <link>/api/reference/40220399</link>
          <label>5. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN Guidelines with the level of evidence. Cancers. 2020;12:E738., DOI: 10.3390/cancers12030738</label>
          <listPosition>5</listPosition>
          <doi>10.3390/cancers12030738</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220400</mtid>
          <link>/api/reference/40220400</link>
          <label>6. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23., DOI: 10.1056/NEJMoa1003466</label>
          <listPosition>6</listPosition>
          <doi>10.1056/NEJMoa1003466</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220401</mtid>
          <link>/api/reference/40220401</link>
          <label>7. McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S. MDX010-20 investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24:2694–8., DOI: 10.1093/annonc/mdt291</label>
          <listPosition>7</listPosition>
          <doi>10.1093/annonc/mdt291</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220402</mtid>
          <link>/api/reference/40220402</link>
          <label>8. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64., DOI: 10.1016/S1470-2045(09)70334-1</label>
          <listPosition>8</listPosition>
          <doi>10.1016/S1470-2045(09)70334-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220403</mtid>
          <link>/api/reference/40220403</link>
          <label>9. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017;35:3851–8., DOI: 10.1200/JCO.2016.72.1985</label>
          <listPosition>9</listPosition>
          <doi>10.1200/JCO.2016.72.1985</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220404</mtid>
          <link>/api/reference/40220404</link>
          <label>10. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90., DOI: 10.1056/NEJMoa1712126</label>
          <listPosition>10</listPosition>
          <doi>10.1056/NEJMoa1712126</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220405</mtid>
          <link>/api/reference/40220405</link>
          <label>11. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab Plus lpilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9., DOI: 10.1200/JCO.2017.76.9901</label>
          <listPosition>11</listPosition>
          <doi>10.1200/JCO.2017.76.9901</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220406</mtid>
          <link>/api/reference/40220406</link>
          <label>12. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564., DOI: 10.1001/jamaoncol.2020.4564</label>
          <listPosition>12</listPosition>
          <doi>10.1001/jamaoncol.2020.4564</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220407</mtid>
          <link>/api/reference/40220407</link>
          <label>13. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86., DOI: 10.1016/S0140-6736(20)32714-8</label>
          <listPosition>13</listPosition>
          <doi>10.1016/S0140-6736(20)32714-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220408</mtid>
          <link>/api/reference/40220408</link>
          <label>14. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211., DOI: 10.1016/S1470-2045(20)30641-0</label>
          <listPosition>14</listPosition>
          <doi>10.1016/S1470-2045(20)30641-0</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220409</mtid>
          <link>/api/reference/40220409</link>
          <label>15. Agarwala SS, Ribas A. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother. 2010;33:557–69., DOI: 10.1097/CJI.0b013e3181dcd260</label>
          <listPosition>15</listPosition>
          <doi>10.1097/CJI.0b013e3181dcd260</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220410</mtid>
          <link>/api/reference/40220410</link>
          <label>16. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40., DOI: 10.1016/S0140-6736(21)00797-2</label>
          <listPosition>16</listPosition>
          <doi>10.1016/S0140-6736(21)00797-2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220411</mtid>
          <link>/api/reference/40220411</link>
          <label>17. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17., DOI: 10.1016/S0140-6736(14)60958-2</label>
          <listPosition>17</listPosition>
          <doi>10.1016/S0140-6736(14)60958-2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220412</mtid>
          <link>/api/reference/40220412</link>
          <label>18. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with Pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67., DOI: 10.1056/NEJMoa2112651</label>
          <listPosition>18</listPosition>
          <doi>10.1056/NEJMoa2112651</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220413</mtid>
          <link>/api/reference/40220413</link>
          <label>19. Grob JJ, Gonzalez R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II Trial (KEYNOTE-629). J Clin Oncol. 2020;38:2916–25., DOI: 10.1200/JCO.19.03054</label>
          <listPosition>19</listPosition>
          <doi>10.1200/JCO.19.03054</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220414</mtid>
          <link>/api/reference/40220414</link>
          <label>20. Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32:1276–85., DOI: 10.1016/j.annonc.2021.07.008</label>
          <listPosition>20</listPosition>
          <doi>10.1016/j.annonc.2021.07.008</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220415</mtid>
          <link>/api/reference/40220415</link>
          <label>21. O’Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study. J Clin Oncol. 2022;40:752–61., DOI: 10.1200/JCO.21.01874</label>
          <listPosition>21</listPosition>
          <doi>10.1200/JCO.21.01874</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220416</mtid>
          <link>/api/reference/40220416</link>
          <label>22. Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: a subgroup analysis of Asian patients in Phase 3 KEYNOTE-240 Trial. Liver Cancer. 2021;10:275–84., DOI: 10.1159/000515553</label>
          <listPosition>22</listPosition>
          <doi>10.1159/000515553</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220417</mtid>
          <link>/api/reference/40220417</link>
          <label>23. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65., DOI: 10.1016/S1470-2045(20)30445-9</label>
          <listPosition>23</listPosition>
          <doi>10.1016/S1470-2045(20)30445-9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220418</mtid>
          <link>/api/reference/40220418</link>
          <label>24. Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized Phase 1 clinical trial. JAMA Oncol. 2020;6:1766–72., DOI: 10.1001/jamaoncol.2020.4515</label>
          <listPosition>24</listPosition>
          <doi>10.1001/jamaoncol.2020.4515</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220419</mtid>
          <link>/api/reference/40220419</link>
          <label>25. Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10:e003777., DOI: 10.1136/jitc-2021-003777</label>
          <listPosition>25</listPosition>
          <doi>10.1136/jitc-2021-003777</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220420</mtid>
          <link>/api/reference/40220420</link>
          <label>26. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65., DOI: 10.1016/S1470-2045(20)30539-8</label>
          <listPosition>26</listPosition>
          <doi>10.1016/S1470-2045(20)30539-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220421</mtid>
          <link>/api/reference/40220421</link>
          <label>27. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905., DOI: 10.1056/NEJMoa1915745</label>
          <listPosition>27</listPosition>
          <doi>10.1056/NEJMoa1915745</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220422</mtid>
          <link>/api/reference/40220422</link>
          <label>28. Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835–44., DOI: 10.1016/S0140-6736(20)30934-X</label>
          <listPosition>28</listPosition>
          <doi>10.1016/S0140-6736(20)30934-X</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220423</mtid>
          <link>/api/reference/40220423</link>
          <label>29. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593., DOI: 10.1126/science.aar3593</label>
          <listPosition>29</listPosition>
          <doi>10.1126/science.aar3593</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220424</mtid>
          <link>/api/reference/40220424</link>
          <label>30. Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449–58., DOI: 10.1038/s41591-018-0101-z</label>
          <listPosition>30</listPosition>
          <doi>10.1038/s41591-018-0101-z</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220425</mtid>
          <link>/api/reference/40220425</link>
          <label>31. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–8., DOI: 10.1038/nature25501</label>
          <listPosition>31</listPosition>
          <doi>10.1038/nature25501</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220426</mtid>
          <link>/api/reference/40220426</link>
          <label>32. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171:934–949.e16., DOI: 10.1016/j.cell.2017.09.028</label>
          <listPosition>32</listPosition>
          <doi>10.1016/j.cell.2017.09.028</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220427</mtid>
          <link>/api/reference/40220427</link>
          <label>33. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477–86., DOI: 10.1038/s41591-018-0337-7</label>
          <listPosition>33</listPosition>
          <doi>10.1038/s41591-018-0337-7</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220428</mtid>
          <link>/api/reference/40220428</link>
          <label>34. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11., DOI: 10.1126/science.aad0095</label>
          <listPosition>34</listPosition>
          <doi>10.1126/science.aad0095</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220429</mtid>
          <link>/api/reference/40220429</link>
          <label>35. Hwang S, Kwon AY, Jeong JY, Kim S, Kang H, Park J, et al. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. 2020;10:643., DOI: 10.1038/s41598-019-57218-9</label>
          <listPosition>35</listPosition>
          <doi>10.1038/s41598-019-57218-9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220430</mtid>
          <link>/api/reference/40220430</link>
          <label>36. Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T, et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 2017;77:3540–50., DOI: 10.1158/0008-5472.CAN-16-3556</label>
          <listPosition>36</listPosition>
          <doi>10.1158/0008-5472.CAN-16-3556</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220431</mtid>
          <link>/api/reference/40220431</link>
          <label>37. Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25:1916–27., DOI: 10.1038/s41591-019-0654-5</label>
          <listPosition>37</listPosition>
          <doi>10.1038/s41591-019-0654-5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220432</mtid>
          <link>/api/reference/40220432</link>
          <label>38. Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019;47:D419–26., DOI: 10.1093/nar/gky1038</label>
          <listPosition>38</listPosition>
          <doi>10.1093/nar/gky1038</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220433</mtid>
          <link>/api/reference/40220433</link>
          <label>39. Menyhart O, Weltz B, Győrffy B. MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction. PLoS One. 2021;16:e0245824., DOI: 10.1371/journal.pone.0245824</label>
          <listPosition>39</listPosition>
          <doi>10.1371/journal.pone.0245824</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220434</mtid>
          <link>/api/reference/40220434</link>
          <label>40. Eddy JA, Thorsson V, Lamb AE, Gibbs DL, Heimann C, Yu JX, et al. CRI iAtlas: an interactive portal for immuno-oncology research. F1000Res. 2020;9:1028., DOI: 10.12688/f1000research.25141.1</label>
          <listPosition>40</listPosition>
          <doi>10.12688/f1000research.25141.1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220435</mtid>
          <link>/api/reference/40220435</link>
          <label>41. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184:596–614.e14., DOI: 10.1016/j.cell.2021.01.002</label>
          <listPosition>41</listPosition>
          <doi>10.1016/j.cell.2021.01.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220436</mtid>
          <link>/api/reference/40220436</link>
          <label>42. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359:801–6., DOI: 10.1126/science.aan5951</label>
          <listPosition>42</listPosition>
          <doi>10.1126/science.aan5951</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220437</mtid>
          <link>/api/reference/40220437</link>
          <label>43. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–37., DOI: 10.1158/2159-8290.CD-15-1545</label>
          <listPosition>43</listPosition>
          <doi>10.1158/2159-8290.CD-15-1545</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220438</mtid>
          <link>/api/reference/40220438</link>
          <label>44. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–995., DOI: 10.1093/nar/gks1193</label>
          <listPosition>44</listPosition>
          <doi>10.1093/nar/gks1193</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220439</mtid>
          <link>/api/reference/40220439</link>
          <label>45. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207–10., DOI: 10.1093/nar/30.1.207</label>
          <listPosition>45</listPosition>
          <doi>10.1093/nar/30.1.207</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220440</mtid>
          <link>/api/reference/40220440</link>
          <label>46. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35–44., DOI: 10.1016/j.cell.2016.02.065</label>
          <listPosition>46</listPosition>
          <doi>10.1016/j.cell.2016.02.065</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220441</mtid>
          <link>/api/reference/40220441</link>
          <label>47. Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021;125:1251–60., DOI: 10.1038/s41416-021-01488-6</label>
          <listPosition>47</listPosition>
          <doi>10.1038/s41416-021-01488-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220442</mtid>
          <link>/api/reference/40220442</link>
          <label>48. DeVito NC, Sturdivant M, Thievanthiran B, Xiao C, Plebanek MP, Salama AKS, et al. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 2021;35:109071., DOI: 10.1016/j.celrep.2021.109071</label>
          <listPosition>48</listPosition>
          <doi>10.1016/j.celrep.2021.109071</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220443</mtid>
          <link>/api/reference/40220443</link>
          <label>49. Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10:346–59., DOI: 10.1159/000515305</label>
          <listPosition>49</listPosition>
          <doi>10.1159/000515305</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220444</mtid>
          <link>/api/reference/40220444</link>
          <label>50. Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018;24:1545–9., DOI: 10.1038/s41591-018-0157-9</label>
          <listPosition>50</listPosition>
          <doi>10.1038/s41591-018-0157-9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220445</mtid>
          <link>/api/reference/40220445</link>
          <label>51. Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35:238–55., DOI: 10.1016/j.ccell.2019.01.003</label>
          <listPosition>51</listPosition>
          <doi>10.1016/j.ccell.2019.01.003</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220446</mtid>
          <link>/api/reference/40220446</link>
          <label>52. Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature. 2021;591:652–8., DOI: 10.1038/s41586-021-03326-4</label>
          <listPosition>52</listPosition>
          <doi>10.1038/s41586-021-03326-4</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220447</mtid>
          <link>/api/reference/40220447</link>
          <label>53. van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clin Cancer Res. 2021;27:3351–9., DOI: 10.1158/1078-0432.CCR-20-4443</label>
          <listPosition>53</listPosition>
          <doi>10.1158/1078-0432.CCR-20-4443</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220448</mtid>
          <link>/api/reference/40220448</link>
          <label>54. Mamdani H, Schneider B, Perkins SM, Burney HN, Kasi PM, Abushahin LI, et al. A Phase II trial of adjuvant durvalumab following trimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma: A Big Ten Cancer Research Consortium Study. Front Oncol. 2021;11:736620., DOI: 10.3389/fonc.2021.736620</label>
          <listPosition>54</listPosition>
          <doi>10.3389/fonc.2021.736620</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220449</mtid>
          <link>/api/reference/40220449</link>
          <label>55. Sarhadi VK, Armengol G. Molecular biomarkers in cancer. Biomolecules. 2022;12:1021., DOI: 10.3390/biom12081021</label>
          <listPosition>55</listPosition>
          <doi>10.3390/biom12081021</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220450</mtid>
          <link>/api/reference/40220450</link>
          <label>56. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363–76., DOI: 10.1056/NEJMoa2201445</label>
          <listPosition>56</listPosition>
          <doi>10.1056/NEJMoa2201445</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220451</mtid>
          <link>/api/reference/40220451</link>
          <label>57. Kacew A, Sweis RF. FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer. Front Immunol. 2020;11:575258., DOI: 10.3389/fimmu.2020.575258</label>
          <listPosition>57</listPosition>
          <doi>10.3389/fimmu.2020.575258</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220452</mtid>
          <link>/api/reference/40220452</link>
          <label>58. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016;4:563–8., DOI: 10.1158/2326-6066.CIR-15-0274</label>
          <listPosition>58</listPosition>
          <doi>10.1158/2326-6066.CIR-15-0274</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220453</mtid>
          <link>/api/reference/40220453</link>
          <label>59. Chen S, Zhang N, Shao J, Wang T, Wang X. Multi-omics perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration in urothelial cancer. J Cancer. 2019;10:697–707., DOI: 10.7150/jca.28494</label>
          <listPosition>59</listPosition>
          <doi>10.7150/jca.28494</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220454</mtid>
          <link>/api/reference/40220454</link>
          <label>60. Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers. 2021;13:2968., DOI: 10.3390/cancers13122968</label>
          <listPosition>60</listPosition>
          <doi>10.3390/cancers13122968</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220455</mtid>
          <link>/api/reference/40220455</link>
          <label>61. Zengin ZB, Chehrazi-Raffle A, Salgia NJ, Muddasani R, Ali S, Meza L, et al. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urol Oncol: Semin Original Investig. 2022;40:25–36., DOI: 10.1016/j.urolonc.2021.10.003</label>
          <listPosition>61</listPosition>
          <doi>10.1016/j.urolonc.2021.10.003</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220456</mtid>
          <link>/api/reference/40220456</link>
          <label>62. Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 2019;7:1457–71., DOI: 10.1158/2326-6066.CIR-18-0595</label>
          <listPosition>62</listPosition>
          <doi>10.1158/2326-6066.CIR-18-0595</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220457</mtid>
          <link>/api/reference/40220457</link>
          <label>63. Liu ST, Pham H, Pandol SJ, Ptasznik A. Src as the link between inflammation and cancer. Front Physiol. 2014;4:416., DOI: 10.3389/fphys.2013.00416</label>
          <listPosition>63</listPosition>
          <doi>10.3389/fphys.2013.00416</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220458</mtid>
          <link>/api/reference/40220458</link>
          <label>64. Roskoski R. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9–25., DOI: 10.1016/j.phrs.2015.01.003</label>
          <listPosition>64</listPosition>
          <doi>10.1016/j.phrs.2015.01.003</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220459</mtid>
          <link>/api/reference/40220459</link>
          <label>65. Basu A. The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy. Pharmacol Ther. 2022;230:107943., DOI: 10.1016/j.pharmthera.2021.107943</label>
          <listPosition>65</listPosition>
          <doi>10.1016/j.pharmthera.2021.107943</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220460</mtid>
          <link>/api/reference/40220460</link>
          <label>66. Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol. 2020;1248:201–26., DOI: 10.1007/978-981-15-3266-5_9</label>
          <listPosition>66</listPosition>
          <doi>10.1007/978-981-15-3266-5_9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220461</mtid>
          <link>/api/reference/40220461</link>
          <label>67. Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138:1120–36., DOI: 10.1182/blood.2020006785</label>
          <listPosition>67</listPosition>
          <doi>10.1182/blood.2020006785</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220462</mtid>
          <link>/api/reference/40220462</link>
          <label>68. Vogler M. Targeting BCL2-proteins for the treatment of solid tumours. Adv Med. 2014;2014:943648., DOI: 10.1155/2014/943648</label>
          <listPosition>68</listPosition>
          <doi>10.1155/2014/943648</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220463</mtid>
          <link>/api/reference/40220463</link>
          <label>69. Szulzewsky F, Holland EC, Vasioukhin V. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Dev Biol. 2021;475:205–21., DOI: 10.1016/j.ydbio.2020.12.018</label>
          <listPosition>69</listPosition>
          <doi>10.1016/j.ydbio.2020.12.018</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220464</mtid>
          <link>/api/reference/40220464</link>
          <label>70. Wang S, Zhou L, Ling L, Meng X, Chu F, Zhang S, et al. The crosstalk between Hippo-YAP pathway and innate immunity. Front Immunol. 2020;11:323., DOI: 10.3389/fimmu.2020.00323</label>
          <listPosition>70</listPosition>
          <doi>10.3389/fimmu.2020.00323</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220465</mtid>
          <link>/api/reference/40220465</link>
          <label>71. Wei C, Li X. The role of photoactivated and non-photoactivated verteporfin on tumor. Front Pharmacol. 2020;11:557429., DOI: 10.3389/fphar.2020.557429</label>
          <listPosition>71</listPosition>
          <doi>10.3389/fphar.2020.557429</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220466</mtid>
          <link>/api/reference/40220466</link>
          <label>72. Yong J, Li Y, Lin S, Wang Z, Xu Y. Inhibitors targeting YAP in gastric cancer: current status and future perspectives. Drug Des Dev Ther. 2021;15:2445–56., DOI: 10.2147/DDDT.S308377</label>
          <listPosition>72</listPosition>
          <doi>10.2147/DDDT.S308377</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220467</mtid>
          <link>/api/reference/40220467</link>
          <label>73. Barsyte-Lovejoy D, Li F, Oudhoff MJ, Tatlock JH, Dong A, Zeng H, et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc Natl Acad Sci USA. 2014;111:12853–8., DOI: 10.1073/pnas.1407358111</label>
          <listPosition>73</listPosition>
          <doi>10.1073/pnas.1407358111</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220468</mtid>
          <link>/api/reference/40220468</link>
          <label>74. Monteiro FL, Williams C, Helguero LA. A systematic review to define the multi-faceted role of lysine methyltransferase SETD7 in cancer. Cancers. 2022;14:1414., DOI: 10.3390/cancers14061414</label>
          <listPosition>74</listPosition>
          <doi>10.3390/cancers14061414</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220469</mtid>
          <link>/api/reference/40220469</link>
          <label>75. Oudhoff MJ, Freeman SA, Couzens AL, Antignano F, Kuznetsova E, Min PH, et al. Control of the hippo pathway by Set7-dependent methylation of Yap. Dev Cell. 2013;26:188–94., DOI: 10.1016/j.devcel.2013.05.025</label>
          <listPosition>75</listPosition>
          <doi>10.1016/j.devcel.2013.05.025</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220470</mtid>
          <link>/api/reference/40220470</link>
          <label>76. Oudhoff MJ, Braam MJS, Freeman SA, Wong D, Rattray DG, Wang J, et al. SETD7 controls intestinal regeneration and tumorigenesis by regulating Wnt/β-Catenin and Hippo/YAP signaling. Dev Cell. 2016;37:47–57., DOI: 10.1016/j.devcel.2016.03.002</label>
          <listPosition>76</listPosition>
          <doi>10.1016/j.devcel.2016.03.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220471</mtid>
          <link>/api/reference/40220471</link>
          <label>77. Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10:101., DOI: 10.1186/s13045-017-0471-6</label>
          <listPosition>77</listPosition>
          <doi>10.1186/s13045-017-0471-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220472</mtid>
          <link>/api/reference/40220472</link>
          <label>78. Chiang C, Yang H, Zhu L, Chen C, Chen C, Zuo Y, et al. The epigenetic regulation of nonhistone proteins by SETD7: New targets in cancer. Front Genet. 2022;13:918509., DOI: 10.3389/fgene.2022.918509</label>
          <listPosition>78</listPosition>
          <doi>10.3389/fgene.2022.918509</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220473</mtid>
          <link>/api/reference/40220473</link>
          <label>79. Meng F, Cheng S, Ding H, Liu S, Liu Y, Zhu K, et al. Discovery and optimization of novel, selective histone methyltransferase SET7 inhibitors by pharmacophore- and docking-based virtual screening. J Med Chem. 2015;58:8166–81., DOI: 10.1021/acs.jmedchem.5b01154</label>
          <listPosition>79</listPosition>
          <doi>10.1021/acs.jmedchem.5b01154</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220474</mtid>
          <link>/api/reference/40220474</link>
          <label>80. Ding H, Lu WC, Hu JC, Liu YC, Zhang CH, Lian FL, et al. Identification and characterizations of novel, selective histone methyltransferase SET7 inhibitors by Scaffold Hopping- and 2D-molecular fingerprint-based similarity search. Molecules. 2018;23:E567., DOI: 10.3390/molecules23030567</label>
          <listPosition>80</listPosition>
          <doi>10.3390/molecules23030567</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220475</mtid>
          <link>/api/reference/40220475</link>
          <label>81. Takemoto Y, Ito A, Niwa H, Okamura M, Fujiwara T, Hirano T, et al. Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7/9 (Set7/9) that regulates estrogen-dependent transcription. J Med Chem. 2016;59:3650–60., DOI: 10.1021/acs.jmedchem.5b01732</label>
          <listPosition>81</listPosition>
          <doi>10.1021/acs.jmedchem.5b01732</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220476</mtid>
          <link>/api/reference/40220476</link>
          <label>82. Li D, Guo J, Jia R. Histone code reader SPIN1 is a promising target of cancer therapy. Biochimie 2021;191:78–86., DOI: 10.1016/j.biochi.2021.09.002</label>
          <listPosition>82</listPosition>
          <doi>10.1016/j.biochi.2021.09.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220477</mtid>
          <link>/api/reference/40220477</link>
          <label>83. Wang JX, Zeng Q, Chen L, Du JC, Yan XL, Yuan HF, et al. SPINDLIN1 promotes cancer cell proliferation through activation of WNT/TCF-4 signaling. Mol Cancer Res. 2012;10:326–35., DOI: 10.1158/1541-7786.MCR-11-0440</label>
          <listPosition>83</listPosition>
          <doi>10.1158/1541-7786.MCR-11-0440</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220478</mtid>
          <link>/api/reference/40220478</link>
          <label>84. Han F, Hu M, Zhang L, Fan X, Wang J, Lou Z, et al. A-to-I RNA editing of BLCAP promotes cell proliferation by losing the inhibitory of Rb1 in colorectal cancer. Exp Cell Res. 2022;417:113209., DOI: 10.1016/j.yexcr.2022.113209</label>
          <listPosition>84</listPosition>
          <doi>10.1016/j.yexcr.2022.113209</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220479</mtid>
          <link>/api/reference/40220479</link>
          <label>85. Gromova I, Svensson S, Gromov P, Moreira JMA. Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer. PLoS One. 2017;12:e0188827., DOI: 10.1371/journal.pone.0188827</label>
          <listPosition>85</listPosition>
          <doi>10.1371/journal.pone.0188827</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220480</mtid>
          <link>/api/reference/40220480</link>
          <label>86. Moreira JMA, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE, et al. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteom. 2010;9:161–77., DOI: 10.1074/mcp.M900294-MCP200</label>
          <listPosition>86</listPosition>
          <doi>10.1074/mcp.M900294-MCP200</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40220481</mtid>
          <link>/api/reference/40220481</link>
          <label>87. Huang YT, Wu TS, Lu CC, Yu FY, Liu BH. Aristolochic acid I interferes with the expression of BLCAP tumor suppressor gene in human cells. Toxicol Lett. 2018;291:129–37., DOI: 10.1016/j.toxlet.2018.03.032</label>
          <listPosition>87</listPosition>
          <doi>10.1016/j.toxlet.2018.03.032</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
      </references>
      <link>/api/publication/33754849</link>
      <label>Kovács Szonja Anna et al. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. (2023) ACTA PHARMACOLOGICA SINICA 1671-4083 1745-7254 44 9 1879-1889</label><template>&lt;div class=&quot;JournalArticle Publication short-list&quot;&gt; &lt;div class=&quot;authors&quot;&gt; &lt;span class=&quot;author-name&quot; mtid=&quot;10081093&quot;&gt; &lt;a href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10081093&quot; target=&quot;_blank&quot;&gt;Kovács, Szonja Anna&lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; mtid=&quot;10063867&quot;&gt; &lt;a href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10063867&quot; target=&quot;_blank&quot;&gt;Fekete, János Tibor&lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; mtid=&quot;10000109&quot;&gt; &lt;a href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10000109&quot; target=&quot;_blank&quot;&gt;Győrffy, Balázs ✉&lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; &lt;/div &gt;&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;33754849&quot; mtid=&quot;33754849&quot; target=&quot;_blank&quot;&gt;Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors&lt;/a&gt;&lt;/div&gt; &lt;div class=&quot;pub-info&quot;&gt; &lt;span class=&quot;journal-title&quot;&gt;ACTA PHARMACOLOGICA SINICA&lt;/span&gt; &lt;span class=&quot;journal-volume&quot;&gt;44&lt;/span&gt; : &lt;span class=&quot;journal-issue&quot;&gt;9&lt;/span&gt; &lt;span class=&quot;page&quot;&gt; pp. 1879-1889. , 11 p. &lt;/span&gt; &lt;span class=&quot;year&quot;&gt;(2023)&lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;pub-end&quot;&gt;&lt;div class=&quot;identifier-list&quot;&gt; &lt;span class=&quot;identifiers&quot;&gt; &lt;span class=&quot;id identifier oa_GOLD&quot; title=&quot; Gold &quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;10.1038/s41401-023-01079-6&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.1038/s41401-023-01079-6&quot;&gt; DOI &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;000970965200001&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/000970965200001&quot;&gt; WoS &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;85152646595&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85152646595&quot;&gt; Scopus &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;37055532&quot; target=&quot;_blank&quot; href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=37055532&amp;dopt=Abstract&quot;&gt; PubMed &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_NONE&quot; title=&quot; None &quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152646595&amp;doi=10.1038%2Fs41401-023-01079-6&amp;partnerID=40&amp;md5=976dbeadcfdb60024eec42b09b6cb2c2&quot; target=&quot;_blank&quot; href=&quot;https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152646595&amp;doi=10.1038%2Fs41401-023-01079-6&amp;partnerID=40&amp;md5=976dbeadcfdb60024eec42b09b6cb2c2&quot;&gt; Other URL &lt;/a&gt; &lt;/span&gt; &lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;short-pub-prop-list&quot;&gt; &lt;span class=&quot;deleted-record&quot;&gt;Centrally managed&lt;/span&gt; &lt;span class=&quot;short-pub-mtid&quot;&gt; Publication:33754849 &lt;/span&gt; &lt;span class=&quot;status-holder&quot;&gt;&lt;span class=&quot;status-data status-APPROVED&quot;&gt; Published &lt;/span&gt;&lt;/span&gt; &lt;span class=&quot;pub-core&quot;&gt;Core Citing &lt;/span&gt; &lt;span class=&quot;pub-type&quot;&gt;Journal Article (Article ) &lt;/span&gt; &lt;!-- &amp;&amp; !record.category.scientific --&gt; &lt;span class=&quot;pub-category&quot;&gt;Scientific&lt;/span&gt; &lt;div class=&quot;publication-citation&quot; style=&quot;margin-left: 0.5cm;&quot;&gt; &lt;span title=&quot;&quot; class=&quot;citingPub-count&quot;&gt;Citing papers: 156&lt;/span&gt; | Independent citation: 150 | Self citation: 6 | Unknown citation: 0 | Number of citations in WoS: 150 | Number of citations in Scopus:&amp;nbsp;101 | WoS/Scopus assigned:&amp;nbsp;156 | Number of citations with DOI:&amp;nbsp;156 &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;</template><template2>&lt;div class=&quot;JournalArticle Publication long-list&quot;&gt;
&lt;div class=&quot;authors&quot;&gt;
	&lt;img title=&quot;Forrásközlemény&quot; style=&quot;float: left&quot; src=&quot;/frontend/resources/grid/publication-core-icon.png&quot;&gt;
	&lt;img title=&quot;Idézőközlemény&quot; style=&quot;float: left&quot; src=&quot;/frontend/resources/grid/publication-citation-icon.png&quot;&gt;

		&lt;div class=&quot;autype autype0&quot;&gt;				&lt;span class=&quot;author-name&quot; mtid=&quot;10081093&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10081093&quot; target=&quot;_blank&quot;&gt;Kovács Szonja Anna
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Kovács Szonja Anna&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; Molekuláris biológia&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Research Centre for Natural Sciences&quot;&gt;RCNS&lt;/span&gt;/&lt;span title=&quot;Institute of Molecular Life Sciences&quot;&gt;IMLS&lt;/span&gt;/Enzim_417; &lt;span title=&quot;Semmelweis University&quot;&gt;SU&lt;/span&gt;/&lt;span title=&quot;Faculty of Medicine&quot;&gt;FM&lt;/span&gt;/&lt;span title=&quot;Instituties&quot;&gt;I&lt;/span&gt;/Bioinformatika Tanszék; &lt;span title=&quot;Semmelweis University&quot;&gt;SU&lt;/span&gt;/School of PhD Studies&lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; mtid=&quot;10063867&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10063867&quot; target=&quot;_blank&quot;&gt;Fekete János Tibor
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Fekete János Tibor&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; Prediktív biomarkerek&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Research Centre for Natural Sciences&quot;&gt;RCNS&lt;/span&gt;/&lt;span title=&quot;Institute of Molecular Life Sciences&quot;&gt;IMLS&lt;/span&gt;/Enzim_417&lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; mtid=&quot;10000109&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10000109&quot; target=&quot;_blank&quot;&gt;Győrffy Balázs ✉
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Győrffy Balázs&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; Onkológia&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Research Centre for Natural Sciences&quot;&gt;RCNS&lt;/span&gt;/&lt;span title=&quot;Institute of Molecular Life Sciences&quot;&gt;IMLS&lt;/span&gt;/Enzim_417; &lt;span title=&quot;Semmelweis University&quot;&gt;SU&lt;/span&gt;/&lt;span title=&quot;Faculty of Medicine&quot;&gt;FM&lt;/span&gt;/&lt;span title=&quot;Instituties&quot;&gt;I&lt;/span&gt;/Bioinformatika Tanszék; &lt;span title=&quot;Semmelweis University&quot;&gt;SU&lt;/span&gt;/&lt;span title=&quot;Faculty of Medicine&quot;&gt;FM&lt;/span&gt;/&lt;span title=&quot;Clinical&quot;&gt;C&lt;/span&gt;/Department of Pediatrics&lt;/span&gt;

				    &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;33754849&quot; target=&quot;_blank&quot;&gt;Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors&lt;/a&gt;&lt;/div&gt;    &lt;div&gt;		&lt;span class=&quot;journal-title&quot;&gt;ACTA PHARMACOLOGICA SINICA&lt;/span&gt;

        &lt;span class=&quot;journal-issn&quot;&gt;(&lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/1671-4083&quot;&gt;1671-4083&lt;/a&gt; &lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/1745-7254&quot;&gt;1745-7254&lt;/a&gt;)&lt;/span&gt;:
		&lt;span class=&quot;journal-volume&quot;&gt;44&lt;/span&gt; &lt;span class=&quot;journal-issue&quot;&gt;9&lt;/span&gt;
&lt;span class=&quot;page&quot;&gt;
	pp 1879-1889
			
&lt;/span&gt;		 &lt;span class=&quot;year&quot;&gt;(2023)&lt;/span&gt;  
    &lt;/div&gt;
&lt;div class=&quot;pub-footer&quot;&gt;
    

	&lt;span class=&quot;language&quot; xmlns=&quot;http://www.w3.org/1999/html&quot;&gt;Language:
			English
		 |  &lt;/span&gt;

	&lt;span class=&quot;identifiers&quot;&gt;
						&lt;span class=&quot;id identifier oa_GOLD&quot; title=&quot;	Gold
&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;10.1038/s41401-023-01079-6&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.1038/s41401-023-01079-6&quot;&gt;
									DOI
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;000970965200001&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/000970965200001&quot;&gt;
									WoS
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;85152646595&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85152646595&quot;&gt;
									Scopus
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;37055532&quot; target=&quot;_blank&quot; href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=37055532&amp;dopt=Abstract&quot;&gt;
									PubMed
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_NONE&quot; title=&quot;	None
&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152646595&amp;doi=10.1038%2Fs41401-023-01079-6&amp;partnerID=40&amp;md5=976dbeadcfdb60024eec42b09b6cb2c2&quot; target=&quot;_blank&quot; href=&quot;https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152646595&amp;doi=10.1038%2Fs41401-023-01079-6&amp;partnerID=40&amp;md5=976dbeadcfdb60024eec42b09b6cb2c2&quot;&gt;
									Other URL
							&lt;/a&gt;
						&lt;/span&gt;
	&lt;/span&gt;


	&lt;OnlyViewableByAuthor&gt;&lt;div class=&quot;ratings&quot;&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Journal subject: Scopus - Medicine (miscellaneous)&amp;nbsp;&amp;nbsp;&amp;nbsp;Rank:&amp;nbsp;D1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Journal subject: Scopus - Pharmacology (medical)&amp;nbsp;&amp;nbsp;&amp;nbsp;Rank:&amp;nbsp;D1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Journal subject: Scopus - Pharmacology&amp;nbsp;&amp;nbsp;&amp;nbsp;Rank:&amp;nbsp;D1&lt;/div&gt;
    &lt;/div&gt;&lt;/OnlyViewableByAuthor&gt;


	&lt;div class=&quot;publication-citation&quot; style=&quot;margin-left: 0.5cm;&quot;&gt;
		&lt;span title=&quot;&quot; class=&quot;citingPub-count&quot;&gt;Citing papers: 156&lt;/span&gt;
		| Independent citation: 150
		| Self citation: 6
		| Unknown citation: 0
		| Number of citations in WoS: 150 
		|  Number of citations in Scopus:&amp;nbsp;101 
		|  WoS/Scopus assigned:&amp;nbsp;156 
		|  Number of citations with DOI:&amp;nbsp;156 
		
	&lt;/div&gt;
    
    
	&lt;div class=&quot;publication-citation&quot;&gt;
		&lt;a target=&quot;_blank&quot; href=&quot;/api/publication?cond=citations.related;eq;33754849&amp;sort=publishedYear,desc&amp;sort=title&quot;&gt;
			Number of cited publications: 4
		&lt;/a&gt;
	&lt;/div&gt;



    &lt;div class=&quot;mtid&quot;&gt;&lt;span class=&quot;long-pub-mtid&quot;&gt;Publication: 33754849&lt;/span&gt;
    | &lt;span class=&quot;status-data status-APPROVED&quot;&gt; 	Published
  &lt;/span&gt;
        
	
	
Core	 Citing
	
	
    | &lt;span class=&quot;type-subtype&quot;&gt;Journal Article
			( Article
			
			)
		&lt;/span&gt;
      		| &lt;span class=&quot;pub-category&quot;&gt;Scientific&lt;/span&gt;
	| &lt;span class=&quot;publication-sourceOfData&quot;&gt;kézi felvitel&lt;/span&gt;
&lt;/div&gt;

&lt;div class=&quot;funder&quot;&gt; (Open access funding provided by Semmelweis University),    Nemzeti Gyógyszerkutatási és Fejlesztési Laboratórium (PharmaLab)(RRF-2.3.1-21-2022-00015) Funder: NRDIO,    National Laboratory of Translational Neuroscience (TINL)(RRF-2.3.1-21-2022-00011),    (TKP-2021-NVA-15) Funder: NRDIO,    (2020-1.1.6-JOVO-2021-00013),    (KDP-14-3/PALY-2021),    (ELIXIR Hungary)   &lt;/div&gt;
&lt;div class=&quot;lastModified&quot;&gt;Last Modified: 2024.02.06. 13:54 Kinga Sonnevend (SE_AOK_Adm5_Élet_kutcsop, admin)
&lt;/div&gt;


        &lt;div class=&quot;lockedBy&quot;&gt;Centrally managed 2024.04.04. 12:41  Andrea Vándor (VA, admin)
        &lt;/div&gt;


	&lt;pre class=&quot;comment&quot; style=&quot;margin-top: 0; margin-bottom: 0;&quot;&gt;&lt;u&gt;Comments&lt;/u&gt;: Department of Bioinformatics, Semmelweis University, Tűzoltó utca 7-9, Budapest, 1094, Hungary            
            Doctoral School of Pathological Sciences, Semmelweis University, Üllői út 26, Budapest, 1085, Hungary            
            National Laboratory for Drug Research and Development, Magyar tudósok körútja 2 1117, Budapest, Hungary            
            Research Centre for Natu...&lt;/pre&gt;
&lt;/div&gt;&lt;/div&gt;</template2>
    </publication>
  </content>
</myciteResult>
